drugset
drugset / Trial / NCT01639625

Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application

NCT01639625 ↗

Phase 2 Completed 18 enrolled Laboratorio Elea Phoenix S.A.
NaSingle-groupOpen-label

Summary

They include patients who are candidates to complete concurrent treatment with endocavitary brachytherapy External radiation therapy + more QT based weekly cisplatin.

Timeline

Start
2011-05
Primary completion
2015-09
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CIGB300 Peptide 15 mg Other
Subject CIGB300 Peptide 35 mg Other
Subject CIGB300 Peptide 70 mg Other

Indications

cervical adenocarcinoma cervical squamous cell carcinoma